JB
$14.91
-0.22
(-1.45%)
As of Oct 22, 2026, 9:32 PM EDT · cached
Price history
Jade Biosciences Inc (JBIO) is trading down at $14.91 (-1.45%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Jade Biosciences Inc net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$8.89M | −$23.0M | −$53.2M | −$81.4M | −$74.6M | −$113.5M |
| Net income | −$9.61M | −$23.0M | −$51.5M | −$75.5M | −$69.6M | −$127.4M |
| EPS (diluted) | −$40.31 | −$1.87 | −$2.10 | −$2.87 | −$2.44 | −$3.19 |
| Balance sheet | ||||||
| Cash and equivalents | $4.57M | $54.2M | $22.4M | $23.5M | $69.4M | $88.4M |
| Total assets | $4.71M | $175.4M | $135.3M | $127.4M | $72.8M | $349.8M |
| Total liabilities | $1.77M | $2.94M | $8.56M | $18.0M | $119.6M | $17.3M |
| Shareholders' equity | −$13.3M | $172.4M | $126.7M | $109.5M | −$46.8M | $332.5M |
| Cash flow | ||||||
| Operating cash flow | −$7.86M | −$27.4M | −$39.1M | −$56.8M | −$71.2M | −$94.7M |
| Capital expenditure | — | $181.0K | $195.0K | $142.0K | — | $196.0K |
| Free cash flow | — | −$27.6M | −$39.3M | −$56.9M | — | −$94.9M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$15.0M | −$8.85M | −$23.4M | −$27.8M | −$27.4M | −$35.0M | −$43.4M | −$58.9M |
| Net income | −$16.3M | −$5.39M | −$38.2M | −$32.1M | −$25.2M | −$31.9M | −$40.4M | −$55.8M |
| EPS (diluted) | −$5.16 | $4.41 | −$12.10 | −$0.86 | −$0.48 | $10.25 | −$0.57 | −$0.76 |
| Balance sheet | ||||||||
| Cash and equivalents | $31.1M | $69.4M | $44.2M | $220.9M | $50.1M | $88.4M | $55.1M | $107.3M |
| Total assets | $91.0M | $72.8M | $77.5M | $224.0M | $202.4M | $349.8M | $319.4M | $472.1M |
| Total liabilities | $10.5M | $119.6M | $2.49M | $22.4M | $23.1M | $17.3M | $23.0M | $32.2M |
| Shareholders' equity | −$16.9M | −$46.8M | −$83.5M | $201.6M | $179.3M | $332.5M | $296.5M | $439.9M |
| Cash flow | ||||||||
| Operating cash flow | −$16.0M | −$11.0M | −$18.8M | −$20.2M | −$22.1M | −$33.6M | −$24.1M | −$43.7M |
| Capital expenditure | — | — | — | — | $57.0K | $3.00K | — | — |
| Free cash flow | — | — | — | — | −$22.2M | −$33.7M | — | — |
From Jade Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Jade Biosciences Inc
- Headquarters
- Waltham, Massachusetts From SEC filings, Oct 2026
Recent News (3)
-
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on de…
-
H.C. Wainwright reiterates Jade Biosciences stock rating at buy
H.C. Wainwright reiterates Jade Biosciences stock rating at buy
-
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International